These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 22502944)

  • 1. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins.
    Lindberg J; Klevebring D; Liu W; Neiman M; Xu J; Wiklund P; Wiklund F; Mills IG; Egevad L; Grönberg H
    Eur Urol; 2013 Feb; 63(2):347-53. PubMed ID: 22502944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Analysis of Localized High-Risk Prostate Cancer Circulating Tumor Cells at the Single-Cell Level.
    Rangel-Pozzo A; Liu S; Wajnberg G; Wang X; Ouellette RJ; Hicks GG; Drachenberg D; Mai S
    Cells; 2020 Aug; 9(8):. PubMed ID: 32784507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
    Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mitochondrial and autosomal mutation landscapes of prostate cancer.
    Lindberg J; Mills IG; Klevebring D; Liu W; Neiman M; Xu J; Wikström P; Wiklund P; Wiklund F; Egevad L; Grönberg H
    Eur Urol; 2013 Apr; 63(4):702-8. PubMed ID: 23265383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer.
    Kim TM; Jung SH; Baek IP; Lee SH; Choi YJ; Lee JY; Chung YJ; Lee SH
    J Pathol; 2014 Aug; 233(4):425-35. PubMed ID: 24870262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
    VanderWeele DJ; Finney R; Katayama K; Gillard M; Paner G; Imoto S; Yamaguchi R; Wheeler D; Lack J; Cam M; Pontier A; Nguyen YTM; Maejima K; Sasaki-Oku A; Nakano K; Tanaka H; Vander Griend D; Kubo M; Ratain MJ; Miyano S; Nakagawa H
    Eur Urol Focus; 2019 May; 5(3):416-424. PubMed ID: 29398457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity.
    Løvf M; Zhao S; Axcrona U; Johannessen B; Bakken AC; Carm KT; Hoff AM; Myklebost O; Meza-Zepeda LA; Lie AK; Axcrona K; Lothe RA; Skotheim RI
    Eur Urol; 2019 Mar; 75(3):498-505. PubMed ID: 30181068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
    Gillard M; Lack J; Pontier A; Gandla D; Hatcher D; Sowalsky AG; Rodriguez-Nieves J; Vander Griend D; Paner G; VanderWeele D
    Eur Urol Focus; 2019 May; 5(3):433-442. PubMed ID: 29229583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial Intratumor Genomic Heterogeneity within Localized Prostate Cancer Revealed by Single-nucleus Sequencing.
    Su F; Zhang W; Zhang D; Zhang Y; Pang C; Huang Y; Wang M; Cui L; He L; Zhang J; Zou L; Zhang J; Li W; Li L; Shao J; Ma J; Xiao F; Liu M
    Eur Urol; 2018 Nov; 74(5):551-559. PubMed ID: 29941308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genome-wide detection of allelic genetic variation to predict advanced-stage prostate cancer after radical prostatectomy using an exome SNP chip.
    Oh JJ; Park S; Lee SE; Hong SK; Lee S; Jo JK; Lee JK; Ho JN; Yoon S; Byun SS
    Urol Oncol; 2015 Sep; 33(9):385.e7-13. PubMed ID: 26087972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variations in the exome of the LNCaP prostate cancer cell line.
    Spans L; Atak ZK; Van Nieuwerburgh F; Deforce D; Lerut E; Aerts S; Claessens F
    Prostate; 2012 Sep; 72(12):1317-27. PubMed ID: 22213130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis of prostate cancer aggressiveness.
    Feik E; Schweifer N; Baierl A; Sommergruber W; Haslinger C; Hofer P; Maj-Hes A; Madersbacher S; Gsur A
    Prostate; 2013 Sep; 73(13):1413-26. PubMed ID: 23813660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 Immunostaining guided laser capture microdissection (p53-LCM) defines the presence of p53 gene mutations in focal regions of primary prostate cancer positive for p53 protein.
    Griewe GL; Dean RC; Zhang W; Young D; Sesterhenn IA; Shanmugam N; McLeod DG; Moul JW; Srivastava S
    Prostate Cancer Prostatic Dis; 2003; 6(4):281-5. PubMed ID: 14663467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tracking the origin of metastatic prostate cancer.
    Lindberg J; Kristiansen A; Wiklund P; Grönberg H; Egevad L
    Eur Urol; 2015 May; 67(5):819-22. PubMed ID: 25246081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of somatic copy number alterations in cancer using targeted exome capture sequencing.
    Lonigro RJ; Grasso CS; Robinson DR; Jing X; Wu YM; Cao X; Quist MJ; Tomlins SA; Pienta KJ; Chinnaiyan AM
    Neoplasia; 2011 Nov; 13(11):1019-25. PubMed ID: 22131877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases.
    Mehra R; Han B; Tomlins SA; Wang L; Menon A; Wasco MJ; Shen R; Montie JE; Chinnaiyan AM; Shah RB
    Cancer Res; 2007 Sep; 67(17):7991-5. PubMed ID: 17804708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer.
    Kristiansen A; Bergström R; Delahunt B; Samaratunga H; Guðjónsdóttir J; Grönberg H; Egevad L; Lindberg J
    Prostate; 2019 Jun; 79(8):920-928. PubMed ID: 30908670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer.
    Pandha H; Sorensen KD; Orntoft TF; Langley S; Hoyer S; Borre M; Morgan R
    BJU Int; 2012 Sep; 110(6 Pt B):E287-92. PubMed ID: 22583908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA ploidy and proliferation heterogeneity in human prostate cancers.
    Shankey TV; Jin JK; Dougherty S; Flanigan RC; Graham S; Pyle JM
    Cytometry; 1995 Sep; 21(1):30-9. PubMed ID: 8529468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.